TVAX may be a clever play on the company's methods but it is completely serious about killing cancer. TVAX Biomedical uses cancer cell vaccination and the introduction of killer T cells to treat cancer. Its TVAX Immunotherapy uses a process of injecting a patient with their own irradiated cancer cells, producing a cancer-specific T cell immune response. The company then harvests those cells from the patient's blood, turns them into killer T cells, and re-injects them. The patient's own immune system does the rest, killing the cancer cells and cancer stem cells, which are normally resistant to treatment methods. TVAX, whose lead candidates attack brain and kidney cancer, withdrew its IPO in May 2012.